Allergenic components of the mRNA‐1273 vaccine for COVID‐19: Possible involvement of polyethylene glycol and IgG‐mediated complement activation

Following the emergency use authorization of the mRNA‐1273 vaccine on the 18th of December 2020, two mRNA vaccines are in current use for the prevention of coronavirus disease 2019 (COVID‐19). For both mRNA vaccines, the phase III pivotal trials excluded individuals with a history of allergy to vacc...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Allergy (Copenhagen) Ročník 76; číslo 11; s. 3307 - 3313
Hlavní autori:	Klimek, Ludger, Novak, Natalija, Cabanillas, Beatriz, Jutel, Marek, Bousquet, Jean, Akdis, Cezmi A.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Denmark Blackwell Publishing Ltd 01.11.2021 Wiley John Wiley and Sons Inc
Predmet:	2019-nCoV Vaccine mRNA-1273 Allergens Allergies Anaphylaxis Complement Activation Contrast media Coronaviruses COVID COVID-19 COVID-19 Vaccines Gadolinium Humans Immunoglobulin E Immunoglobulin G Immunoglobulin M Life Sciences Lipids mRNA mRNA vaccines Opsonization Polyethylene glycol Polyethylene Glycols Review SARS-CoV-2 SARS‐CoV Trometamol United States vaccines COVID vaccines SARS-CoV
ISSN:	0105-4538, 1398-9995, 1398-9995
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!